U of A celebrates commercial potential of research More…

Benign prostatic hyperplasia may not sound familiar, but it affects 50 per cent of men over the age of 50. This condition is characterized by an enlarged prostate and causes uncomfortable urinary tract symptoms that affect men’s quality of life.

The condition isn’t preventable, but can be treated with IMBiotechnologies Ltd’s new medical device, EkobiTM Embolization Microspheres. Approved by Health Canada, EkobiTM treats enlarged prostates through artery embolization, a non-surgical technique that uses tiny beads to selectively block blood flow to the portion of the prostate that puts pressure on the urethra. As a result, the urinary tract symptoms improve. In addition to lowering urinary tract symptoms, EkobiTM   can also treat hypervascularized tumours such as liver and kidney cancers.

With a life-changing product in tow, IMBiotechnologies leveraged Edmonton’s regional innovation network to accelerate product development. Through press releases announcing 510(k) FDA clearance and intellectual property and market assessments through Alberta Innovates’ voucher programs, EkobiTM is now for sale in Canada and the USA.

Today, IMBiotechnologies is conducting a clinical study at the University of Alberta to treat uterine fibroids, a benign tumour that affects over 60 per cent of women over the age of 45. Unlike the permanent implants currently on the market, EkobiTM microspheres are biodegradable and detectable by ultrasound, providing a unique and enhanced level of safety.

Learn more about TEC Edmonton’s Technology Management services. Connect with us.

 

This is a story from our 2017/18 annual report. Read more stories from the annual report here.

Through the Go Get Fit app, which gamifies physical activity, healthcare professionals provide fitness guidance to patients, track their progress, and support them in making fitness a part of their lifestyle. The app connects healthcare providers with community-based exercise specialists. This connection supports patients in their everyday life where transformation takes place. Endurance Unlimited first engaged with TEC Edmonton in late 2016, when TEC provided market strategy insight which in part, led to partner connections. In 2017, TEC Edmonton facilitated:

  • Endurance Unlimited’s attendance and participation in the Accelerating Primary CarE (AICE) Conference.
  • An application to the Alberta Innovates Accelerating Innovations into CarE (AICE) program – a collaboration between Healthy Heart Institute (Central Alberta Cardiovascular Sciences Department) and Endurance Unlimited.

Additionally, in March 2018, the Go Get Fit app was a finalist in Edmonton’s Smart Cities HealthHack competition.

Learn more about the TEC Health Accelerator: www.tecedmonton.com/health-accelerator

Edmonton, AB, Canada (January 16, 2019). Effective June 30, 2019, Chris Lumb will resign as the chief executive officer of TEC Edmonton, a joint venture between the University of Alberta (UAlberta) and Edmonton Economic Development (EEDC). Since December 2009, Lumb has led the not-for-profit that accelerates emerging technology companies and commercializes UAlberta research into business opportunities.

“On behalf of the board, we thank Chris for his tremendous work leading the TEC Edmonton team and being an instrumental force in developing Edmonton as a leader in innovation and entrepreneurship,” said Wayne Karpoff, chair, TEC Edmonton board of directors. “Over the last decade, we’ve been fortunate to have Chris’s expertise, determination and passion. The growth we’ve seen over the last several years is very much in part due to Chris. We wish him the best in the next chapter of his journey.”

“On behalf of the University of Alberta, I thank Chris for his leadership. He helped TEC Edmonton grow into one of the world’s top university-linked accelerators,” says Dr. Matthias Ruth, Vice-President Research, University of Alberta. “Under Chris’s tenure, hundreds of research-driven technologies were licensed and over 110 university spin-off companies were created to commercialize research discoveries. We wish him luck in his next chapter.”

“Through his leadership at TEC Edmonton, Chris has made many contributions to the success of entrepreneurs,” says Cheryll Watson, VP of Innovate Edmonton. “I’d like to sincerely thank him for his contributions to Edmonton.”

Over the next few months, Lumb is committed to focusing on TEC’s strategic positioning, program offerings and community partnerships. TEC Edmonton’s board of directors will initiate an executive search for Lumb’s successor in the coming weeks.

“After nearly ten years with TEC Edmonton, I decided this was the right time to step down and bring a new perspective to the organization,” said Chris Lumb, CEO, TEC Edmonton. “With outstanding staff and management, a strong culture and excellent client outcomes, TEC will continue to do outstanding work helping to grow emerging technology companies in the community.”

After June 30, Lumb plans to continue working directly with Edmonton-based entrepreneurial ventures and in research commercialization.

-30-

About TEC Edmonton

TEC Edmonton is a business accelerator that helps emerging technology companies grow successfully. As a joint venture of the University of Alberta and Edmonton Economic Development, TEC Edmonton operates the Edmonton region’s largest accelerator for early-stage technology companies and manages commercialization of University of Alberta technologies.

Since 2011, TEC clients have generated over $1 billion in revenue, raised $504M in financing and funding, invested $278M in R&D, and grown both revenue and employment by 37 per cent per year and now employ over 2,200 people in the region. TEC has assisted in the creation of 37 spin-off companies from the University of Alberta in the last seven years.

TEC Edmonton was named the 3rd best University Business Accelerator in the world by the University Business Incubator (UBI) Global Index in 2018. For more information, visit TECEdmonton.com.

For more information, contact:
Jennifer Sheehan
Director, Communications and Marketing, TEC Edmonton
jennifer.sheehan@tecedmonton.com
P: 780-492-0707
C: 587-920-8172

Posted: Aug 12, 2019

Telebivudine to Abrogate Amyotrophic Lateral Sclerosis

Description Telbivudine Dr. Ted Allison and his team at the University of Alberta have discovered that telbivudine, a blood brain barrier-permeable thymidine analogue approved for treatment of Hepatitis B, is......


Posted: Jun 14, 2019

A Point-of-Care Diagnostic Tool to Replace Chest X-Ray for the Diagnosis of Childhood Pneumonia

Description University of Alberta researchers have discovered a novel set of biomarkers which can be used to diagnose pneumonia in children. The biomarkers include chitinase-3-like-1 (CHI3L1), lipocalin-2 (LCN-2), C-reactive protein......


Posted: Jun 14, 2019

Novel Cell Isolation Method for Bio-engineering Artificial Cartilage

Description University of Alberta researchers have developed a new method to isolate cells from knee joint (meniscus). The isolated cells are non-contractile in nature and do not form scar tissue.......


Posted: Jun 13, 2019

Novel Composite Monolith as a New Solid Phase Extraction Material for Environmental Analysis

Description University of Alberta researchers have developed a new material of a composite silica monolith nested in sponge (SiMNS) for solid phase extraction. The application of the new SiMNS material......


Posted: May 21, 2019

Self Assembling Peptide for Activating Human Mast Cells

Description Researchers at the University of Alberta have developed a novel biomaterial that can activate the body’s own innate immune response and accelerate the wound healing process. This technology may......


Posted: May 21, 2019

An Innocuous Structured Scaffold for Prion Disease Vaccines and Antigens

Description Researchers at the University of Alberta, led by Dr. Holger Wille, have developed a novel strategy for the creation of vaccines and specific antigens for prion protein diseases. Applying......


Posted: May 21, 2019

Spine Mounted Stereotactic System

Description Demonstration of stereotactic setup. An example of a commercially-available micromanipulator is shown. The setup can accommodate any micromanipulator design. Dr. Vivian Mushahwar and her team have developed an image-guided......


Posted: May 15, 2019

Method for the Production of Z-Olefins from 1,3-Dienes

Description Dr. Rylan Lundgren has developed a process for formate-mediated production of Z-olefins (also referred to as cis-alkenes) in the presence of a rhodium-based catalyst. The process is highly selective......


Posted: Apr 3, 2019

A Novel Method to Produce Pitched Kefir for Reducing Cholesterol

Description Researchers at the University of Alberta and TEAGASC have jointly developed a pitched-based method to produce kefir (a fermented milk beverage) that when consumed reduces blood cholesterol levels. The......


Posted: Nov 5, 2018

Novel F-18 Beta-Hydroxybutyric Acid Radiotracers for PET Imaging

Description Researchers at the University of Alberta have synthesized novel beta-hydroxybutyric acid radiotracers for PET imaging using a 3 step radiosynthetic process. The compounds are designed to serve as radiofluorinated......


Posted: Nov 5, 2018

A Novel Method for CryoPreservation of Cells in Monolayers

Description Researchers at the University of Alberta have developed a novel method to cryopreserve cells while adhered in a monolayer configuration. This method can preserve cells on a substrate and......


Posted: Oct 30, 2018

Train-Triggered Alert System for Conditioning and Warning Wildlife

Description Researchers at the University of Alberta have developed a novel, inexpensive, and compact system to alert wildlife to approaching trains, increasing the time available to avoid a collision. Rail-caused......